{"id":448707,"date":"2026-02-04T15:26:07","date_gmt":"2026-02-04T15:26:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/448707\/"},"modified":"2026-02-04T15:26:07","modified_gmt":"2026-02-04T15:26:07","slug":"amd-slumps-on-no-new-big-customer-wins-with-unexpected-china-sales-driving-ai-revenue-beat","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/448707\/","title":{"rendered":"AMD slumps on no new big customer wins, with unexpected China sales driving AI revenue beat"},"content":{"rendered":"

Novo Nordisk\u2019s slide continues after CEO warns of \u201cunprecedented pricing pressure\u201d as outlook overshadows Q4 results<\/a><\/p>\n

Novo Nordisk\u2019s<\/a> shares are tumbling further in premarket trading on Wednesday after CEO Mike Doustdar warned that the Danish pharma giant will face \u201cunprecedented\u201d price pressures in 2026, addressing the company\u2019s annual sales forecast<\/a>, which showed a decline in revenue.<\/p>\n

\u201cOur 2026 guidance reflects a year of unprecedented pricing pressure,\u201d Doustdar said on a call with journalists<\/a>, adding in an interview with CNBC<\/a> that people should expect that US pricing \u201cgoes down before it comes back up,\u201d as headwinds from lower US Wegovy pricing remain.<\/p>\n

On Tuesday, NVO shares fell double digits after it forecast that sales and operating profit for 2026 will both decline by between 5% and 13% \u2014 analysts were expecting very modest growth in each.<\/p>\n

In its 2025 annual report<\/a>, released on Wednesday morning, the company detailed the disappointing guidance, citing \u201clower realised prices, including the MFN (\u2018Most Favoured Nations\u2019) agreement in the US and the loss of exclusivity for the semaglutide molecule in certain markets in International Operations.\u201d Novo also added that \u201cpositive impacts related to US gross-to-net sales adjustments during 2025 are not anticipated to reoccur.\u201d <\/p>\n

Across its actual Q4 results, things were a little rosier: sales and diluted EPS figures for Q4 2025 came in at $12.3 billion and $0.94, respectively, slightly beating analyst consensus estimates in both cases by 0.9% and 1.4% (forecasts compiled by Bloomberg). <\/p>\n

Meanwhile, Eli Lilly<\/a> reported quarterly earnings results and posted 2026 guidance on Wednesday that crushed Wall Street estimates<\/a>. Indeed, though Novo was first to the GLP-1 market, Lilly is proving fierce competition, having surpassed the Danish giant\u2019s sales by Q2 of last year.<\/a> The Mounjaro maker\u2019s earnings on Wednesday showed that the gap is only getting wider.<\/p>\n

Just as Novo launched a new oral GLP-1 for weight loss in January \u2014 and early signs show uptake is strong<\/a> \u2014 Lilly also has a weight-loss pill expected to come to market later this year. Novo is facing patent expiry for semaglutide, the active ingredient in Ozempic and Wegovy, starting this year in major markets like Canada, India, and China.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk\u2019s slide continues after CEO warns of \u201cunprecedented pricing pressure\u201d as outlook overshadows Q4 results Novo Nordisk\u2019s…\n","protected":false},"author":2,"featured_media":448708,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[182,181,507,74],"class_list":{"0":"post-448707","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-artificial-intelligence","8":"tag-ai","9":"tag-artificial-intelligence","10":"tag-artificialintelligence","11":"tag-technology"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/448707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=448707"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/448707\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/448708"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=448707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=448707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=448707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}